Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Therapeutics Corp

By The Northwire Desk — AI Analysis May 07, 2026 · 07:30 BCT · 5.63 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • Most Recent Event: On May 7, 2026, BriaCell announced the addition of NYU Langone Health’s Perlmutter Cancer Center as a new clinical trial site for its pivotal Phase 3 Bria-ABC study.
  • Study Details: The study evaluates Bria-IMT™ combined with an immune checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer.
  • Regulatory Status: The regimen holds FDA Fast Track designation. Interim analysis is triggered after 144 patient events (deaths).
  • Historical Progression:
    • Jan 2026: Closed $30 million public offering at $5.59/unit, diluting shareholders and depressing stock price from ~$15 to ~$6.
    • Feb-Mar 2026: Received 5th consecutive DSMB safety recommendation; completed asset purchase for sCD80 license with subsidiary BriaPro.
    • Apr 2026: FDA clearance received for next-gen Bria-BRES+ IND; presented data at ASCO and AACR regarding Phase 3 biomarkers and preclinical activity of Bria-OTS+.
    • May 2026 (Current): Expansion of clinical sites to include NYU Langone, reinforcing enrollment capacity ahead of the anticipated H1 2026 top-line data readout.
Material Impact
  • Incremental Nature: The addition of a new clinical site is an operational milestone consistent with previous announcements in October 2025 (Dartmouth, Cedars-Sinai, Emory) and May 2026. It does not constitute a material change to the company's valuation or risk profile compared to prior data readouts or financing events.
  • Enrollment Context: The company reported >160 patients enrolled as of December 2025. Adding major academic centers like NYU Langone supports the timeline for reaching the 144 death event threshold required for interim analysis, which is expected in H1 2026.
  • Market Expectation: The market has already priced in the clinical progression through the stock's stabilization around $5-$6 following the January financing. This news confirms execution but does not introduce new upside catalysts beyond what was anticipated (data readout).
  • Risk Mitigation: Continued safety endorsements from DSMB and site expansion mitigate near-term operational risk, but do not eliminate clinical trial failure risk inherent to late-stage oncology trials.
BCT · Price
Company Overview
  • Company: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on cancer immunotherapy.
  • Flagship Project: Bria-IMT™, an allogenic whole-cell-based cancer vaccine combined with immune checkpoint inhibitors (CPI).
  • Indication: Advanced metastatic breast cancer (MBC) via the Phase 3 Bria-ABC study.
  • Pipeline: Includes next-generation platforms Bria-BRES+ (breast), Bria-PROS+ (prostate), and sCD80 technology licensed to subsidiary BriaPro.
  • Development Stage: Pivotal Phase 3 for Bria-IMT; Phase 1/2a for Bria-BRES+.
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other